Amanda M. Walker

Amanda M. Walker

Auto-generated profile, based on publicly available information

Amanda M. Walker

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
HCHenry W. Chen
Henry W. Chen
AWAmanda M. Walker
Amanda M. Walker
ASAmy Buros Stein
Amy Buros Stein
SCSojung L. Chen
Sojung L. Chen
KSKaila L. Schollaert-Fitch
Kaila L. Schollaert-Fitch
HJHeidi Jacobe
Heidi Jacobe

12 September 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
AWAmanda M. Walker
Amanda M. Walker
BBBonnie L. Bermas
Bonnie L. Bermas
HJHeidi Jacobe
Heidi Jacobe

9 April 2021 in Case Reports in Dermatological Medicine
Verified
Journal Article
Open access
PDF file
AWAmanda Walker
Amanda Walker
VSVikram Nath Sahni
Vikram Nath Sahni
DSDev Ram Sahni
Dev Ram Sahni
JCJulia Curtis
Julia Curtis
Reflectance confocal microscopy (RCM) is an emerging and noninvasive imaging tool in dermatological practice. Benefits of this modality include differentiation between benign and malignant skin lesions, prevention of unnecessary biopsies, and cost effectiveness. However, RCM findings for benign lesions are rarely reported in the literature. We describe a case of reflectance confocal microscopy findings of a hidrocystoma and review potential applications of this imaging technique in everyday clinical practice.

25 March 2022 in Case Reports in Dermatological Medicine
Verified
Journal Article
Open access
PDF file
AWA. Walker
A. Walker
JWJ. S. Westerdahl
J. S. Westerdahl
JZJ. Zussman
J. Zussman
JMJ. Mathis
J. Mathis
Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE inhibitors, antihistamines, beta-blockers, antidepressants, and anticonvulsants. Ustekinumab is a human monoclonal antibody that targets inflammatory cytokines IL-12 and IL-23 and has been have shown to be effective in treating IGDR. However, we present a case that suggests ustekinumab can also act as an inciting agent for IGDR.

15 March 2023 in Dermatology
Verified
Journal Article
Closed access
PDF file
HCHenry W Chen
Henry W Chen
JCJennifer Coias
Jennifer Coias
AWAmanda M. Walker
Amanda M. Walker
SPSmriti Prasad
Smriti Prasad
LMLiqiao Ma
Liqiao Ma
HJHeidi Jacobe
Heidi Jacobe
Background: In many fields of medicine, guidelines recommend reduced cancer screening in patients of advanced age with limited life expectancy (LLE). In dermatology, there are currently no guidelines for adjusted evaluation and management practices of keratinocyte cancer (KC) in patients with LLE. Little is known regarding evaluation and management patterns and frequency of biopsies in these patients. Objective: We sought to determine if dermatology providers biopsy LLE patients with similar frequency to their age-matched peers and quantify frequency of associated complications. Methods: This was a retrospective cohort study of evaluations for skin cancer quantified by skin biopsy frequency at the North Texas Veterans Affairs Health System dermatology clinic for 3,062 patients between 2005 and 2009, including a 5-year follow-up period. Life expectancy was quantified by the validated Charlson Comorbidity Index (CCI) with a Deyo adaptation. Results: There was no significant difference in biopsy frequency of KC in LLE versus non-LLE patients in most age-controlled groups, with increased biopsy frequency in LLE patients in the 65–74 age category (p = 0.02). There was also an increased risk of complications from biopsy in the 75–84 (many comorbidities subgroup: RR = 3.27, p = 0.002; some comorbidities subgroup: RR = 2.26, p = 0.048) and 65–74 (many comorbidities subgroup: RR = 1.52, p = 0.004) age groups when compared to age-matched healthy controls. Conclusion: Biopsy frequency is similar or increased in patients with LLE compared with age-matched controls, with increased frequency of complications. Further studies are needed to understand the underlying factors driving these practice patterns.

20 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
AWAmanda M. Walker
Amanda M. Walker
BCBenjamin F. Chong
Benjamin F. Chong